Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) General Information

Description

Intellectual property rights for compositions of matter and methods to make and use genome-edited primary B cells. The intellectual property rights include proprietary methods that cover the delivery of a targeted nuclease into the B cell for precise genome engineering and the resultant compositions of matter.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Minneapolis, MN
  • United States
Primary Industry
Buildings and Property
Acquirer
Corporate Office
  • Minneapolis, MN
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells)‘s full profile, request access.

Request a free trial

Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells)‘s full profile, request access.

Request a free trial

Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) FAQs

  • Where is Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) headquartered?

    Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) is headquartered in Minneapolis, MN.

  • What industry is Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) in?

    Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells)’s primary industry is Buildings and Property.

  • Is Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) a private or public company?

    Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) is a Private company.

  • What is Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells)’s current revenue?

    The current revenue for Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) is .

  • Who are Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells)’s investors?

    Regents of the University of Minnesota has invested in Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells).

  • When was Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) acquired?

    Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) was acquired on 27-Mar-2023.

  • Who acquired Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells)?

    Immusoft (Intellectual Property Rights for Genome-Edited Primary B Cells) was acquired by Immusoft.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process